KRYS
Krystal Biotech, Inc.
Nasdaq: KRYS · Pittsburgh, PA · Healthcare
$272.66-3.84 (-1.39%)Closed
Market Cap$7.96B
Cash$496.3Mmost recent
Runwayprofitable
P/E (TTM)39.9EPS $6.84
52-Wk Range$123.36 – $291.93
Avg Volume326.5K3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$272.66+73.4%
Pipeline

Drug candidates sponsored by Krystal Biotech · ClinicalTrials.gov

13 drugs · 17 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 3Topical Beremagene Geperpavec
Dystrophic Epidermolysis Bullosa+2 more
Completed
2021-10-29past
2
Phase 3Open Label Topical Beremagene Geperpavec (B-VEC)
Dystrophic Epidermolysis Bullosa+3 more
Completed
2023-07-31past
1
Phase 3KB803
Dystrophic Epidermolysis Bullosa+3 more
Recruiting
2026-12
1
Phase 1KB105
TGM-1 Related Autosomal Recessive Congenital Ichthyosis+1 more
Unknown
2024-03past
2
Phase 1KB304
Wrinkles in Decolletage+2 more
Active, not recruiting
2025-07past
1
Phase 1KB801
Neurotrophic Keratitis
Recruiting
2026-12
1
Phase 1KB707
Lung Cancer, Non-small Cell+8 more
Recruiting
2027-02
2
Phase 1KB301
Skin Roughness+3 more
Active, not recruiting
2024-10-16past
1
Phase 1KB407 (Nebulization)
Cystic Fibrosis
Recruiting
2025-12past
2
Phase 1KB408 (Nebulization)
Alpha 1-Antitrypsin Deficiency
Recruiting
2025-12past
1
N/AUnnamed
Dystrophic Epidermolysis Bullosa+1 more
Withdrawn
2020-02-24past
1
N/AUnnamed
Epidermolysis Bullosa Dystrophica+2 more
Recruiting
2025-12past
1
N/AUnnamed
Dystrophic Epidermolysis Bullosa+2 more
Recruiting
2028-05-25
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for KRYS. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.